Genetically engineered and synthetic allergen derivatives: Candidates for vaccination against type I allergy

Biological Chemistry

Volumn 380, Issue 7-8, 1999, Pages 815-824

  Valenta, Rudolf ^a   Vrtala, Susanne ^a   Focke Tejkl, Margit ^a   Bugajska Schretter, Agnes ^a   Ball, Tanja ^a   Twardosz, Anna ^a   Spitzauer, Susanne ^a   Grönlund, Hans ^b   Kraft, Dietrich ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b PFIZER INC   (United States)

Author keywords

Genetic engineering; Immunotherapy; Recombinant allergen; Synthetic peptide; Type I allergy; Vaccination

Indexed keywords

ALLERGEN; HAPTEN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; RECOMBINANT PROTEIN; SYNTHETIC PEPTIDE; VACCINE;

ANAPHYLAXIS; ASTHMA; CONJUNCTIVITIS; CROSS REACTION; GENETIC ENGINEERING; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOTHERAPY; MEDIATOR RELEASE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN FOLDING; REVIEW; RHINITIS; VACCINATION;

EID: 0032826306     PISSN: 14316730     EISSN: None     Source Type: Journal    
DOI: 10.1515/BC.1999.101     Document Type: Review

References (103)

1. Aalberse, R.C., Gaag, R., and Leeuwen, J. (1983). Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an lgG4-restricted response. J. Immunol. 130, 722-726.
2. Adkinson, N.F., Sobotka, A.K., and Lichtenstein, L.M. (1979). Evaluation of the quantity and affinity of human IgG 'blocking' antibodies. J. Immunol. 122, 965-972.
3. 4 responses by conformational antigen variants. Eur. J. Immunol. 28, 914-925.
4. Ball, T., Vrtala, S., Sperr, W.R., Valent, P., Susani, M., Kraft, D., and Valenta, R. (1994). Isolation of an immunodominant IgE-hapten from an epitope expression cDNA library; dissection of the allergic effector reaction. J. Biol. Chem. 269, 28323-28328.
5. Ball, T., Sperr, W.R., Valent, P., Lidholm, J., Spitzauer, S., Ebner, C., Kraft, D., and Valenta, R. (1999a). Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy. Eur. J. Immunol. 29, 2026-2036.
6. Ball, T., Fuchs, T., Sperr, W.R., Valent, P., Vangelista, L., Kraft, D., and Valenta, R. (1999b). B cell epitopes of the major timothy grass pollen allergen, PhI p 1, revealed by gene fragmentation as candidates for immunotherapy. FASEB J. 73, in press.
7. Beaven, M.A., and Metzger, H. (1993). Signal transduction by Fc receptors: the Fc epsilon RI case. Immunol. Today 14, 222-226.
8. Bieber, T. (1996). Fc epsilon RI on antigen-presenting cells. Curr. Opin. Immunol. 8, 773-777.
9. Bousquet, J., Heijaoui, A., Soussana, M., and Michel, F.B. (1990). Double blind placebo controlled immunotherapy with mixed grass pollen allergoids. IV. Comparison of the efficacy and safety of two dosages of a high molecular weight allergoid. J. Allergy Clin. Immunol. 85, 490-497.
10. Bousquet, J., Lockey, R., Malling, H.J., and the WHO panel members (1998). Allergen immunotherapy: Therapeutic vaccines for allergic diseases. A WHO position paper. J. Allergy Clin. Immunol. 102, 558-562.
11. Breiteneder, H., Ferreira, F., Hoffmann-Sommergruber, K., Ebner, C., Breitenbach, M., Rumpold, H., Kraft, D., and Scheiner, O. (1993). Four recombinant isoforms of Cor a I, the major allergen of hazel pollen, show different IgE binding properties. Eur. J. Biochem. 212, 355-362.
12. 2+ depletion. J. Allergy Clin. Immunol. 101, 67-74.
13. Chakrabarty, S., Ekramoddoullah, A.K., Kisil, F.T., and Sehon, A.H. (1980). Allergens of Kentucky Blue Grass pollen. II. Isolation of hapten-like components from Kentucky Blue Grass pollen by preparative isoelectrofocussing. Int. Arch. Allergy Appl. Immunol. 63, 369-382.
14. Cooke, R., Barnard, J., Hebald, S., and Stull, A. (1935). Serological evidence on immunity with co-existing sensitization in a type of human allergy, hay fever. J. Exp. Med. 62, 733-750.
15. Creticos, P.S., Adkinson, N.F., Jr., Kagey-Sobotka, A., Proud, D., Meier, H.L., Naclerio, R.M., Lichtenstein, L.M., and Norman, P.S. (1985). Nasal challenge with ragweed in hay fever patients: Effect of immunotherapy. J. Clin. Invest. 76, 2247-2253.
16. DeWeck, A.L., and Schneider, C.H. (1972). Specific inhibition of allergic reactions to penicillin in man by a monovalent hapten. I. Experimental immunological and toxicologic studies. Int. Arch. Allergy Appl. Immunol. 42, 782-797.
17. Dolecek, C., Steinberger, P., Susani, M., Kraft, D., Valenta, R., and Boltz-Nitulescu, G. (1995). Effects of IL-4 and IL-13 on total and allergen specific IgE production by cultured PBMC from allergic patients determined with recombinant allergens. Clin. Exp. Allergy 25, 879-889.
18. + T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-γ. J. Allergy Clin. Immunol. 97, 1356-1365.
19. Durham, S., Gould, H.J., Thienes, C.P., Jacobson, M.R., Masuyama, K., Rak, S., Lowhagen, O., Schotman, E., Cameron, L., and Hamid, Q.A. (1997). Expression of epsilon germ-line gene transcripts and mRNA for the epsilon heavy chain of IgE in nasal B cells and the effects of topical corticosteroid. Eur. J. Immunol. 27, 2899-2906.
20. Durham, S.R., and Till, S.J. (1998). Immunological changes associated with allergen immunotherapy. J. Allergy Clin. Immunol. 102, 157-164.
21. 1 in T-cell clones specific for PhI p 1, a major grass pollen allergen. Clin. Exp. Allergy 27, 1007-1015.
22. Engel, E., Richter, K., Obermeyer, G., Briza, P., Kungl, A.J., Simon, B., Auer, M., Ebner, C., Rheinberger, H., Breitenbach, M., and Ferreira, F. (1997). Immunological and biological properties of Bet v 4, a novel birch pollen allergen with two EF-hand calcium-binding domains. J. Biol. Chem. 272, 28630-28637.
23. Eriksson, N.E., and Ahlstedt, S. (1977). Diagnosis of reaginic allergy with house dust, animal dander and pollen allergens in adult patients. V. A comparison between the enzyme-linked immunosorbent assay (ELISA), provocation tests, skin tests and RAST. Int. Arch. Allergy Appl. Immunol. 54, 88-95.
24. Fedorov, A.A., Ball, T., Mahoney, N.M., Valenta, R., and Almo, S.C. (1997). The molecular basis for allergen crossreactivity: crystal structure and IgE epitope mapping of birch pollen profilin. Structures 5, 33-45.
25. Ferreira, F., Hirtenlehner, K., Jilek, A., Godnik-Cvar, J., Breiteneder, H., Grimm, R., Hoffmann-Sommergruber, K., Scheiner, O., Kraft, D., Breitenbach, M., Rheinberger, H.J., and Ebner, C. (1996). Dissection of immunoglobulin E and T lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v 1: Potential use of hypoallergenic isoforms for immunotherapy. J. Exp. Med. 183, 599-609.
26. Ferreira, F., Ebner, C., Kramer, B., Casari, G., Briza, P., Kungl, A.J., Grimm, R., Jahn-Schmid, B., Breiteneder, H., Kraft, D., Breitenbach, M., Rheinberger, H., and Scheiner, O. (1998). Modulation of IgE reactivity of allergens by site-directed mutagenesis: potential use of hypoallergenic variants for immunotherapy. FASEB J. 12, 231-242.
27. Focke, M., Ball, T., Mahler, V., Kraft, D., and Valenta, R. (1999). B-cell epitope-derived peptides of the major grass pollen allergen, PhI p 1, for immunotherapy. Allergy 54, Suppl. 52, 19.
28. Fuchs, E. (1979). Clinical diagnosis of allergy. Prax. Klin. Pneumol. 33, 268-276.
29. Furin, M.M., Norman, P.S., Creticos, P.S., Proud, D., Kagey-Sobotka, A., Lichtenstein, L.M., and Naclerio, R.M. (1991). Immunotherapy decreases antigen-induced eosinophil migration into the nasal cavity. J. Allergy Clin. Immunol. 88, 27-32.
30. Gleich, G.J., Zimmermann, E.M., Gleich, M.C., and Yunginger, J.W. (1981). Measurement of IgG blocking antibodies by interference in the radioallergosorbent test. J. Immunol. 126, 575-579.
31. Haas, H., Falcone, F.H., Holland, M.J., Schramm, G., Haisch, K., Gibbs, B.F., Bufe, A., and Schlaak, M. (1999). Early interleukin-4: Its role in the switch towards a Th2 response and IgE-mediated allergy. Int. Arch. Allergy Immunol. 119, 86-94.
32. Hayek, B., Vangelista, L., Pastore, A., Sperr, W.R., Valent, P., Vrtala, S., Niederberger, V., Twardosz, A., Kraft, D., and Valenta, R. (1998). Molecular and immunologic characterization of a highly cross-reactive two EF-hand calcium-binding alder pollen allergen, Aln g 4: Structural basis for calcium-modulated IgE recognition. J. Immunol. 161, 7031-7039.
33. Hedin, H., and Richter, W. (1982). Pathomechanism of dextran-induced anaphylactoid/anaphylactic reactions in man. Int. Arch. Allergy Appl. Immunol. 68, 122-126.
34. Ishizaka, K., Ishizaka, T., and Hornbrook, M.M. (1966). Physicochemical properties of human reaginic antibody. J. Immunol. 97, 840-845.
35. Jensen-Jarolim, E., Leitner, A., Kalchhauser, H., Zurcher, A., Ganglberger, E., Bohle, B., Scheiner, O., Boltz-Nitulescu, G., and Breiteneder, H. (1998). Peptide mimotopes displayed by phage inhibit antibody binding to Bet v 1, the major birch pollen allergen, and induce specific IgG response in mice. FASEB J. 12, 1635-1642.
36. Johansson, S.G.O., and Bennich, H. (1967). Immunological studies of an atypical (myeloma) immunoglobulin. Immunology 13, 381-394.
37. Jutel, M., Pichler, W.J., Skrbic, D., Urwyler, A., Dahinden, C., and Müller, U.R. (1995). Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-γ secretion in specific allergen-stimulated T cell cultures. J. Immunol. 154, 4187-4194.
38. Kay, A.B. (1997). Allergy and Allergic Diseases. (Oxford, U.K.: Blackwell Science).
39. Kolbe, L., Heusser, C., and Kolsch, E. (1991). Antigen dose dependent regulation of B epsilon-memory cell expression. Int. Arch. Allergy Immunol. 95, 202-206.
40. Leitner, A., Vogel, M., Radauer, C., Breiteneder, H., Stadler, B.M., Scheiner, O., Kraft, D., and Jensen-Jarolim, E. (1998). A mimotope defined by phage display inhibits IgE binding to the plant panallergen profilin. Eur. J. Immunol. 28, 2921-2927.
41. Lichtenstein, L.M., Holtzman, N.A., and Burnett, L.S. (1968). A quantitative in vitro study of the chromatographic distribution and immunoglobulin characteristics of human blocking antibody. J. Immunol. 101, 317-324.
42. Litwin, A., Pesce, A.J., and Michael, J.G. (1988). Regulation of the immuneresponse to allergens by immunosuppressive allergenic fragments. I. Peptic fragments of hony bee venom phospholipase A2. Int. Arch. Allergy Appl. Immunol. 87, 361-366.
43. nd edition. (New York, USA: Marcel Dekker).
44. Loveless, M. H. (1940). Immunological studies of pollinosis: I. The presence of two antibodies related to the same pollen antigen in the serum of treated hay fever patients. J. Immunol. 38, 25-50.
45. Loveless, M.H. (1943). Immunological studies on pollinosis. IV. The relationship between thermostable antibody in the circulation and clinical immunity. J. Immunol. 47, 165-180.
46. Malley, A., and Perlman, F. (1969). Induction of both reaginic and blocking antibodies with a low molecular weight fraction of timothy pollen extract. J. Allergy 43, 59-64.
47. Malley, A., Baecher, L., Mackler, B., and Perlman, F. (1976). Further characterization of a low-molecular weight allergen fragment isolated from the green pea. Clin. Exp. Immunol. 25, 159-164.
48. Marsh, D.G., Norman, P.S., Roebber, M., and Lichtenstein, L.M. (1981). Studies of allergoids from naturally occuring allergens. III. Preparation of ragweed pollen allergoids by aldehyde modification in two steps. J. Allergy Clin. Immunol. 68, 449-459.
49. Menz, G., Dolecek, C., Schoenheit-Kenn, U., Ferreira, F., Moser, M., Schneider, T., Suter, M., Boltz-Nitulescu, G., Ebner, C., Kraft, D., and Valenta, R. (1996). Serological and skin test diagnosis of birch pollen allergy with recombinant Bet v 1, the major birch pollen allergen. Clin. Exp. Allergy 26, 50-60.
50. Meriney, D.K., Kothari, H., Chinoy, P., and Grieco, M.H. (1986). The clinical and immunological efficacy of immunotherapy with modified ragweed extract (allergoid) for ragweed hay fever. Allergy 56, 34-38.
51. Müller, U., Akdis, C.A., Fricker, M., Akdis, M., Blesken, T., Bettens, F., and Blaser, K. (1998). Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J. Allergy Clin. Immunol. 101, 747-754.
52. Niederberger, V., Pauli, G., Grönlund, H., Fröschl, R., Rumpold, H., Kraft, D., Valenta, R., and Spitzauer, S. (1998a). Recombinant birch pollen allergens (rBet v 1, rBet v 2) contain most of the IgE epitopes present in birch, alder, hornbeam, hazel, and oak pollen. A quantitative IgE inhibition study using sera from different populations. J. Allergy Clin. Immunol. 102, 579-591.
53. Niederberger, V., Laffer, S., Fröschl, R., Kraft, D., Rumpold, H., Kapiotis, S., Valenta, R., and Spitzauer, S. (1998b). IgE antibodies to recombinant pollen allergens (PhI p 1, PhI p2, PhI p5, and Bet v 2) account for a high percentage of grass pollen-specific IgE. J. Allergy Clin. Immunol. 101, 258-264.
54. Noon, L. (1911). Prophylactic inoculation against hayfever. Lancet 1, 1572-1573.
55. Norman, P.S., Lichtenstein, L.M., Kagey-Sobotka, A., and Marsh, D.G. (1982). Controlled evaluation of allergoid in the immunotherapy of ragweed hay fever. J. Allergy Clin. Immunol. 70, 248-260.
56. Norman, P.S., Ohman, J.L., Jr., Long, A.A., Creticos, P.S., Gefter, M.A., Shaked, Z., Wood, R.A., Eggleston, P.A., Hafner, K.B., Rao, P., Lichtenstein, L.M., Jones, N.H., and Nicodemus, C.F. (1996). Treatment of cat allergy with T-cell reactive peptides. American J. Resp. Critical Care Med. 154, 1623-1628.
57. Norman, P.S., Nicodemus, C.F., Creticos, P.S., Wood, R.A., Eggleston, P.A., Lichtenstein, L.M., Kagey-Sobotka, A., and Proud, D. (1997). Clinical and immunologic effects of component peptides in Allervax® cat. Allergy-a disease of modern society. Int. Arch. Allergy Immunol. 113, 224-226.
58. O'Brien, R. M., Byron, K. A., Varigos, G. A., and Thomas, W. R. (1997). House dust mite immunotherapy results in a decrease in Der p 2-specific IFN-γ and IL-4 expression by circulation T lymphocytes. Clin. Exp. Allergy 27, 46-51.
59. Olsson, S., van Hage-Hamsten, M., and Whitley, P. (1998). Contribution of disulphide bonds to antigenicity of Lep d 2, the major allergen of the dust mite Lepidoglyphus destructor. Mol. Immunol. 35, 1017-1023.
60. Okada, T., Swoboda, I., Bhalla, P.L., Toriyama, K., and Singh, M.B. (1998). Engineering of hypoallergenic mutants of the Brassica pollen allergen, Brar1, for immunotherapy. FEBS Lett. 434, 255-260.
61. Otsuka, H., Mezawa, A., Ohnishi, M., Okubo, K., Sehi, H., and Okuda, M. (1991). Changes in nasal metachromatic cells during allergen immunotherapy. Clin. Exp. Allergy 21, 115-120.
62. Pauli, G., Oster, J.P., Deviller, P., Heiss, S., Bessot, J.C., Susani, M., Ferreira, F., Kraft, D., and Valenta, R. (1996). Skin testing with recombinant allergens rBet v 1 and birch profilin, rBet v 2: diagnostic value for birch pollen and associated allergies. J. Allergy Clin. Immunol. 97, 1100-1109.
63. Pauli, G., Purohit, A., Oster, J.P., Vrtala, S., Niederberger, V., Kraft, D., and Valenta, R. (1999). Clinical evaluation of genetically engineered hypoallergenic rBet v 1 derivatives. Int. Arch. Allergy Immunol. 118, 216-217.
64. Rak, S., Rowhagen, O., and Venge, P. (1988). The effect of immunotherapy on bronchial hyper-responsiveness and eosinophil cationic protein in pollen allergic patients. J. Allergy Clin. Immunol. 82, 470-480.
65. Ravetch, J.V., and Kinet, J.P. (1991). Fc receptors. Ann. Rev. Immunol. 9, 457-492.
66. Richter, W., Hedin, H., Kraft, D., and Messmer, K. (1981). Anaphylactoid reactions after dextran II. Experimental studies in animals on the principle of hapten inhibition. Beitr. Infusionsther. Klin. Ernähr. 8, 54-65.
67. Rolland, J., and O'Hehir, R. (1998). Immunotherapy of allergy: anergy, deletion, and immune deviation. Curr. Opin. Immunol. 10, 640-645.
68. Rothbard, J.B. (1992). Synthetic peptides as vaccines. Biotechnology 20, 451-465.
69. Rocklin, R.E., Sheffer, A., Greineder, D.K., and Melmon, K.L. (1980). Generation of antigen-specific supressor cells during allergy desensitization. N. Engl. J. Med. 302, 1213-1219.
70. Romagnani, S., Maggi, E., del Prete, G.F., Troncone, R., and Ricci, M. (1980). In vitro production of IgE by human blood mononuclear cells. Clin. Exp. Immunol. 42, 167-174.
71. Schramm, G., Kahlert, H., Suck, R., Weber, B., Stuwe, H.J., Müller, W.D., Bufe, A., Becker, W.M., Schlaak, M.W., Jäger, L., Cromwell, O., and Fiebig, H. (1999). 'Allergen engineering': Variants of the timothy grass pollen allergen PhI p 5b with reduced IgE-binding capacity but conserved T cell reactivity. J. Immunol. 162, 2406-2414.
72. + T cells from allergic individuals. J. Exp. Med. 178, 2123-2130.
73. + T cells from allergic individuals is modulated by antigen concentration and antigen-presenting cell type. J. Exp. Med. 181, 1081-1089.
74. 2+. EMBO J. 13, 3481-3486.
75. Simons, F.E., Imada, M., Li, Y., Watson, W.T., and HayGlass, K.T. (1996). Fel d 1 peptides: effect on skin tests and cytokine synthesis in cat-allergic human subjects. Int. Immunol. 8, 1937-1945.
76. Singh, M.B., de Weerd, N., and Bhalla, P.L. (1999). Genetically engineered plant allergens with reduced anaphylactic activity. Int. Arch. Allergy Immunol. 119, 75-85.
77. Smith, A.M., and Chapman, M.D. (1996). Reduction in IgE binding to allergen variants generated by site-directed mutagenesis: contribution of disulfide bonds to the antigenic structure of the major house dust mite allergen Der p 1. Mol. Immunol. 33, 399-405.
78. 2+ binding protein as a new Bermuda grass pollen allergen, Cynd7: IgE cross-reactivity with oilseed rape pollen allergen, Bra r 1. Int. Arch. Allergy Immunol. 114, 265-271.
79. Sobotka, A.K., Valentine, M.D., Ishizaka, K., and Lichtenstein, L.M. (1976). Measurement of IgG blocking antibodies: development and application of a radioimmuno-assay. J. Immunol. 117, 84-90.
80. Steinberger, P., Bohle, B., di Padova, F., Wrann, M., Liehl, E., Scheiner, O., Kraft, D., and Valenta, R. (1995). Allergen-specific IgE production of committed B cells from allergic patients in vitro. J. Allergy Clin. Immunol. 96, 209-218.
81. Stingl, G., and Maurer, D. (1997). IgE-mediated allergen presentation via Fc epsilon RI on antigen-presenting cells. Int. Arch. Allergy Immunol. 113, 24-29.
82. Suphioglu, C., Ferreira, F., and Knox, R.B. (1997). Molecular cloning and immunological characterization of Cyn d 7, a novel calcium-binding allergen from Bermuda grass pollen. FEBS Lett. 402, 167-172.
83. Swoboda, I., Jilek, A., Ferreira, F., Engel, E., Hoffmann-Sommergruber, K., Scheiner, O., Kraft, D., Breiteneder, H., Pittenauer, E., Schmid, E. et al. (1995). Isoforms of Bet v 1, the major birch pollen allergen, analyzed by liquid chromatography, mass spectrometry, and cDNA cloning. J. Biol. Chem. 270, 2607-2613.
84. Swoboda, I., Smith, N., Bhalla, P., Niederberger, V., Ebner, C., Sperr, W.R., Valent, P., Valenta, R., and Singh, M. (1999). Production of hypoallergenic forms of the major ryegrass pollen allergen, LoI p 5, for allergen-specific immunotherapy, submitted.
85. Takai, T., Yokota, T., Yasue, M., Nishiyama, C., Yuuki, T., Mori, A., Okudaira, H., and Okumura, Y. (1997). Engineering of the major house dust mite allergen Der f 2 for allergen-specific immunotherapy. Nature Biotech. 15, 754-758.
86. Tamborini, E., Faccini, S., Lidholm, J., Svensson, M., Brandazza, A., Longhi, R., Grönlund, H., Sidoli, A., and Arosio, A. (1997). Biochemical and immunological characterization of recombinant allergen LoI p 1. Eur. J. Biochem. 249, 886-894.
87. Twardosz, A., Hayek, B., Seiberler, S., Vangelista, L., Elfman, L., Grönlund, H., Kraft, D., and Valenta, R. (1997). Molecular characterization, expression in Escherichia coli, and epitope analysis of a two EF-hand calcium-binding birch pollen allergen, Bet v 4. Biochem. Biophys. Res. Comm. 239, 197-204.
88. Valenta, R., Duchêne, M., Vrtala, S., Birkner, T., Ebner, C., Hirschwehr, R., Breitenbach, M., Rumpold, H., Scheiner, O., and Kraft, D. (1991). Recombinant allergens for immunoblot diagnosis of tree-pollen allergy. J. Allergy Clin. Immunol. 88, 889-894.
89. Valenta, R., Vrtala, S., Ebner, C., Kraft, D., and Scheiner, O. (1992). Diagnosis of grass pollen allergy with recombinant timothy grass (Phleum pratense) pollen allergens. Int. Arch. Allergy Immunol. 97, 287-294.
90. Valenta, R., and Kraft, D. (1995). Recombinant allergens for diagnosis and therapy of allergic diseases. Curr. Opin. Immunol. 7, 751-756.
91. Valenta, R., Steinberger, P., Duchêne, M., Kraft, D. (1996). Immunological and structural similarities among allergens: Prerequisite for a specific and component-based therapy of allergy. Immunol. Cell Biol. 74, 187-194.
92. Valenta, R., Vrtala, S., Laffer, S., Spitzauer, S., and Kraft, D. (1998a). Recombinant allergens. Allergy 53, 552-561.
93. Valenta, R., Almo, S., Ball, T., Dolecek, C., Steinberger, P., Laffer, S., Eibensteiner, P., Flicker, S., Vrtala, S., Spitzauer, S., Valent, P., Denepoux, S., Kraft, D., Banchereau, J., and Lebecque, S. (1998b). The immunoglobulin E-allergen interaction : A target for therapy of type I allergic diseases. Int. Arch. Allergy Immunol. 116, 167-176.
94. Valenta, R., Lidholm, J., Niederberger, V., Hayek, B., Kraft, D., and Grönlund, H. (1999). The recombinant allergen-based concept of component resolved diagnosis and immunotherapy (CRD and CRIT). Clin. Exp. Allergy 29, 896-904.
95. Van Hage-Hamsten, Kronqvist, M., Zetterström, O., Johansson, E., Niederberger, V., Vrtala, S., Grönlund, H., Grönneberg, R., and Valenta, R. (1999). Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen , Bet v 1. Results obtained with a mix of two recombinant Bet v 1 fragments and rBet v 1 trimer in a Swedish population before the birch pollen season. J. Allergy Clin. Immunol., in press.
96. Van Ree, R., van Leeuwen, W.A., Dieges, P.H., van Wijk, R.G., De Jong, N., Brewczyski, P.Z., Kroon, A.M., Schilte, P.P., Tan, K.Y., Simon-Licht, I.F., Roberts, A.M., Stapel, S.O., and Aalberse, R.C. (1997). Measurement of IgE antibodies against purified grass pollen allergens (LoI p 1, 2, 3 and 5) during immunotherapy. Clin. Exp. Allergy 27, 68-74.
97. Vrtala, S., Hirtenlehner, K., Vangelista, L., Pastore, A., Eichler, H.G., Sperr, W.R., Valent, P., Ebner, C., Kraft, D., and Valenta, R. (1997). Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments; candidates for a novel form of specific immunotherapy. J. Clin. Invest. 99, 1673-1681.
98. Vrtala, S., Ball, T., Spitzauer, S., Pandjaitan, B., Suphioglu, C., Knox, B., Sperr, W.R., Valent, P., Kraft, D., and Valenta, R. (1998). Immunization with purified natural and recombinant allergens induces mouse IgG1 antibodies that recognize similar epitopes as human IgE and inhibit the human IgE-allergen interaction and allergen-induced basophil degranulation. J. Immunol. 160, 6137-6144.
99. Vrtala, S., Hirtenlehner, K., Susani, M., Hufnagl, P., Binder, B.R., Vangelista, L., Pastore, A., Sperr, W.R., Valent, P., Ebner, C., Kraft, D., and Valenta, R. (1999). Genetic engineering of recombinant hypoallergenic oligomers of the major birch pollen allergen, Bet v 1: candidates for specific immunotherapy. Int. Arch. Allergy Immunol. 118, 218-219.
100. Wide, L., Bennich, H., and Johansson, S.G. (1967). Diagnosis of allergy by an in vitro test for allergen antibodies. Lancet 2, 1105-1107.
101. Wiedemann, P., Giehl, K., Almo, S.C., Fedorov, A.A., Girvin, M., Steinberger, P., Rüdiger, M., Ortner, M., Sippl, M., Dolecek, C., Kraft, D., Jockusch, B., and Valenta, R. (1996). Molecular and structural analysis of a continuous birch profilin epitope defined by a monoclonal antibody. J. Biol. Chem. 271, 29915-29921.
102. Yang, X., Gieni, R.S., Mosman, T.R., and HayGlass, K.T. (1993). Chemically modified antigen preferentially elicits induction of Th1-like cytokine synthesis patterns in vivo. J. Exp. Med. 178, 349-353.
103. Zeiler, T., Taivainen, A., Rytkonen, M., Rautiainen, J., Karjalainen, H., Mantyjarvi, R., Tuomisto, L., and Virtanen, T. (1997). Recombinant allergen fragments as candidate preparations for allergen immunotherapy. J. Allergy Clin. Immunol. 100, 721-727.